Table 1.

Characteristics of the included studies.

Study Publication Year Clinicaltrials.gov ID	Study Design	Main Inclusion Criteria	Main Exclusion Criteria	Sample Size	Follow Up	Early Aspirin Discontinuation			Standard of Care			Primary Outcomes
						Duration of Aspirin Therapy after Randomization	P2Y12 Inhibitors Use (Dosage)	OAC Agent	DAPT Duration	Antiplatelet Agents	OAC Agent
WOEST [11] 2013 NCT00769938	Randomized, open label, multicentric, superiority, controlled trial	Indication for oral anticoagulation and PCI	>80 years, Prior ICH, cardiogenic shock recent major bleeding, thrombocytopenia	563	12 months	None after randomization	Clopidogrel 100% (75 mg)	VKA	1 to 12 months	Aspirin 80–100 mg; and Clopidogrel 75 mg	VKA	Safety: Any episode of bleeding (defined by TIMI, GUSTO or BARC classification
PIONEER AF-PCI [12] 2016 NCT01830543	Randomized, open label, multicentric, controlled trial	Non-valvular AF PCI with coronary stent implantation	Prior stroke/TIA, recent GI bleeding, severe CKD, anemia increase risk of bleeding contra-indication for OAC Active malignancy	2124	12 months	None after randomization	Clopidogrel 93.1% (75 mg), Ticagrelor 5.2% (90 mg bid), Prasugrel 1.7% (10 mg)	Rivaroxaban 15 mg or 10 mg	1, 6 or 12 months	Aspirin 75–100 mg, and Clopidogrel 75 mg, Ticagrelor 90 mg bid, Prasugrel 10 mg	VKA or Rivaroxaban 2.5 mg	Safety: Composite of: Major and minor TIMI bleeding and bleeding requiring medical attention
REDUAL-PCI [13] 2017 NCT02164864	Phase IIIb, randomized, open label, multicentric, non-inferiority, controlled trial	Non valvular AF Successful PCI < 120 h	Prosthetic heart valves, severe CKD, recent stroke, major surgery or GI bleeding	2725	14 months *	None after randomization	Clopidogrel 86.6% (75 mg), Ticagrelor 12.4% (90 mg bid)	Dabigatran 150 or 110 mg bid	1 month (BMS) 3 months (DES)	Aspirin < 100 mg and Clopidogrel 75 mg, Ticagrelor 90 mg bid	VKA	Safety: Time to event analysis of first major or clinically relevant non major ISTH bleeding
GLOBAL LEADERS [14] 2018 NCT01813435	Randomized, open label, multicentric, superiority, controlled trial	Clinical indication of PCI	Need for OAC, planned surgery, recent stroke, prior major bleeding	15,968	24 months	30 days	Ticagrelor 100% (90 mg bid)	N.A.	12 months	Aspirin 75-100 mg, and Clopidogrel 75 mg, Ticagrelor 90 mg bid	N.A.	Efficacy: Composite of all-cause death or non-fatal, new Q-wave myocardial infarction.
AUGUSTUS [15] 2019 NCT02415400	Multicentric, randomized with two-two factorial design, double blinded, non-inferiority, controlled trial	AF and recent PCI or ACS with planned used of at least 6 months of P2Y12	Other indication for OAC, severe CKD, prior ICH, coagulopathy, planned CABG	4614	6 months	None after randomization	Clopidogrel 93.2% (75 mg) Ticagrelor 5.9% (90 mg bid) Prasugrel 0.9% (10 mg)	Apixaban 5 mg or 2.5 mg bid or VKA	6 months	Aspirin 81 mg, and Clopidogrel 75 mg, Ticagrelor 90 mg bid, Prasugrel 10 mg	Apixaban 5 mg or 2.5 mg bid or VKA	Safety: major or clinically relevant non-major ISTH bleeding
STOPDAPT-2 [16] 2019 NCT02619760	Randomized, open label, multicentric, non inferiority, controlled trial	PCI with CoCr-EES without periprocedural complication	Need for OAC, prior ICH, use of other stents	3009	12 months	1 month	During 1st month Clopidogrel 60.2% (75 mg) Prasugrel 39.6% (10 mg) After 1st month Clopidogrel 100% (75 mg)	N.A.	12 months	Aspirin 81 to 200 mg and Clopidogrel 75 mg or Prasugrel 10 mg before 1 month, Followed by Clopidogrel 75 mg	N.A.	Safety and efficacy: Composite of cardiovascular death, MI, definite stent thrombosis, stroke and TIMI major and minor bleeding
SMART CHOICE [17] 2019 NCT02079194	Randomized, open label, multicentric, non inferiority, controlled trial	PCI with DES for ACS or stable CAD	Hemodynamic instability; active bleeding; recent DES implantation	2993	12 months	3 months	Clopidogrel 76.9% (75 mg) Ticagrelor 6.5% (90 mg bid) Prasugrel 0.7% (10 mg)	investigators choice	12 months	Clopidogrel 75 mg, Ticagrelor 90 mg bid, Prasugrel 10 mg	investigators choice	Efficacy: Composite of all-cause mortality, MI, stroke
ENTRUST-AF PCI [18] 2019 NCT02866175	Phase IIIb, Randomized, open label, multicentric, controlled trial	Non valvular AF and PCI procedure for stable CAD or ACS with success	Valvular or reversible AF, mechanical heart valve, severe CKD, major surgery planned, recent ischemic stroke, high bleeding risk	1506	12 months	None after randomization	Clopidogrel 92.7% (75 mg) Ticagrelor 6.5% (90 mg bid) Prasugrel 0.7% (5 or 10 mg)	Edoxaban 60 mg or 30 mg VKA	1 to 12 months	Aspirin 100 mg, and Clopidogrel 75 mg, Ticagrelor 90 mg bid, Prasugrel 5 or 10 mg	VKA	Safety: Composite of ISTH major and clinically relevant non-major bleeding Efficacy: Composite of CV death, stroke, systemic embolic event, MI and definite ST
TWILIGHT [19] 2019 NCT02270242	Phase IV, randomized, blinded-label, multicentric, superiority controlled trial	High risk patients with complex PCI †	Contraindication to aspirin or ticagrelor, STEMI as index event, need for chronic OAC, prior stroke, planned surgery or coronary revascularization	7119	12 months	None after randomization	Ticagrelor (100%)	N.A.	12 months	Aspirin 81–100 mg and Ticagrelor 90 mg bid	N.A.	Safety: Composite of BARC types 2, 3 or 5 bleeding

* mean follow-up † was defined as the association of at least one criterion among: age > 65 years, female sex, established CV disease, diabetes mellitus, chronic kidney disease, and at least one criterion among: multivessel disease, total stent length > 30 mm, thrombotic lesion, bifurcation, left main or proximal left anterior descending artery. PCI: percutaneous coronary intervention; DAPT: Dual antiplatelet therapy; OAC: oral anticoagulation; VKA: vitamin K antagonist; MI: myocardial infarction; AF: atrial fibrillation; TIA: transient ischemic attack; ICH: intracranial hemorrhage; GI: gastro-intestinal; CKD: Chronic kidney disease; ACS: acute coronary syndrome; CABG: coronary artery bypass graft; CAD: coronary artery disease; CV: cardiovascular; CoCr-EES: cobalt-chromium everolimus eluting stent; N.A.: not applicable; STEMI: ST segment elevation myocardial infarction.